Daptomycin + Vancomycin

ApprovedTerminated

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Staphylococcal Infections

Conditions

Staphylococcal Infections, Methicillin-resistant Staphylococcus Aureus

Trial Timeline

Oct 1, 2010 → Mar 1, 2014

NCT ID

NCT01196169

About Daptomycin + Vancomycin

Daptomycin + Vancomycin is a approved stage product being developed by Merck for Staphylococcal Infections. The current trial status is terminated. This product is registered under clinical trial identifier NCT01196169. Target conditions include Staphylococcal Infections, Methicillin-resistant Staphylococcus Aureus.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01419184	Approved	Completed	Sep 9, 2011	Oct 5, 2012	Staphylococcal Skin Infections
NCT01196169	Approved	Terminated	Oct 1, 2010	Mar 1, 2014	Staphylococcal Infections
NCT01175707	Approved	Terminated	Jul 15, 2010	Nov 17, 2011	Complicated Skin or Skin Structure Infection
NCT00695903	Phase 2	Terminated	Sep 17, 2008	Oct 1, 2010	Endocarditis, Bacterial
NCT00426933	Phase 2	Completed	Jan 1, 2007	Sep 1, 2007	Soft Tissue Infections
NCT00295178	Approved	Completed	Feb 20, 2006	Aug 9, 2006	Cellulitis

Competing Products

20 competing products in Staphylococcal Infections

See all competitors

Product	Company	Stage	Hype Score
Ceftobiprole	Johnson & Johnson	Phase 1	33
Ceftobiprole	Johnson & Johnson	Phase 1	33
Daptomycin 4 mg/kg + Comparator: vancomycin + Daptomycin 6 mg/kg	Merck	Phase 3	77
V710 + Placebo	Merck	Phase 1	33
V710 + Comparator: Placebo	Merck	Phase 1	33
V710 (30 µg) with MAA + V710 (30 µg) without MAA	Merck	Phase 1	33
Daptomycin + Vancomycin	Merck	Approved	85
Daptomycin	Novartis	Approved	85
SA4Ag vaccine	Pfizer	Phase 1	32
Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine	Pfizer	Phase 2	51
linezolid (Zyvox)	Pfizer	Pre-clinical	22
Staphylococcus aureus 4-antigen vaccine + Placebo	Pfizer	Phase 2	51
Tigecycline	Pfizer	Approved	84
SA4Ag vaccine low dose + SA4Ag vaccine mid dose + SA4Ag vaccine high dose + Placebo	Pfizer	Phase 1	32
SA4Ag vaccine low dose + SA4Ag vaccine mid dose + SA4Ag vaccine high dose + SA3Ag vaccine + Placebo	Pfizer	Phase 1	32
NDV-3 vaccine with alum IM + NDV-3 vaccine without alum IM + Placebo with alum IM + NDV-3 vaccine without alum ID	United Therapeutics	Phase 1	30
NDV-3 investigational vaccine	United Therapeutics	Phase 1	30
TD-1792 + Vancomycin	Theravance Biopharma	Phase 2	47
Ceftobiprole	Basilea Pharmaceutica	Phase 1	28
human lactoferrin peptide 1-11	AM-Pharma	Phase 1/2	33

Other Products from Merck

DuleraApproved

ImipenemApproved

Mavenclad®Approved

raltegravir + PlaceboApproved

alendronate sodiumApproved